January 25, 2012

SPECIAL COMMITTEE OF HELIX BIOPHARMA CORP. PROVIDES UPDATE TO SHAREHOLDERS (PDF)

INTERIM REPORT OF ERNST & YOUNG LLP RECEIVED

AURORA, Ontario, January 25, 2012 – The Special Committee of the Board of Directors of Helix BioPharma Corp. (TSX, NYSE Amex, FSE: HBP) (the “Company” or “Helix”) announces that Ernst & Young LLP (“Ernst & Young”) has delivered its Interim Report. As announced on December 6, 2011, the Special Committee engaged Ernst & Young to assist the Special Committee in the investigation of the conduct of certain shareholders and parties related to these shareholders.